Cissy Kityo
#77,592
Most Influential Person Now
Ugandan physician and medical researcher
Cissy Kityo's AcademicInfluence.com Rankings
Cissy Kityolaw Degrees
Law
#3237
World Rank
#4076
Historical Rank
Common Law
#212
World Rank
#229
Historical Rank
Cissy Kityophilosophy Degrees
Philosophy
#10336
World Rank
#14162
Historical Rank
Logic
#8357
World Rank
#10450
Historical Rank
Download Badge
Law Philosophy
Cissy Kityo's Degrees
- Bachelors Medicine Makerere University
- PhD Medical Research Stanford University
Why Is Cissy Kityo Influential?
(Suggest an Edit or Addition)According to Wikipedia, Cissy Kityo Mutuluuza , is a Ugandan physician, epidemiologist and medical researcher. She is the Executive Director of the Joint Clinical Research Centre, a government-owned medical research institution in Uganda, specializing in HIV/AIDS treatment and management.
Cissy Kityo's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Depletion of Regulatory T Cells in HIV Infection Is Associated with Immune Activation1 (2005) (394)
- Multiple Validated Measures of Adherence Indicate High Levels of Adherence to Generic HIV Antiretroviral Therapy in a Resource-Limited Setting (2004) (307)
- HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. (2011) (300)
- Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda (2007) (283)
- Defining total-body AIDS-virus burden with implications for curative strategies (2017) (279)
- Unnecessary Antiretroviral Treatment Switches and Accumulation of HIV Resistance Mutations; Two Arguments for Viral Load Monitoring in Africa (2011) (216)
- Assessment of second-line antiretroviral regimens for HIV therapy in Africa. (2014) (183)
- Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. (2012) (178)
- Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. (2012) (169)
- Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults (2001) (166)
- Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. (2008) (159)
- Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV‐infected patients in Uganda (2007) (136)
- Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa (2017) (136)
- Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa (2006) (130)
- Excellent Adherence to Antiretrovirals in HIV+ Zambian Children Is Compromised by Disrupted Routine, HIV Nondisclosure, and Paradoxical Income Effects (2011) (129)
- Antiretroviral therapy and sexual behavior: a comparative study between antiretroviral- naive and -experienced patients at an urban HIV/AIDS care and research center in Kampala, Uganda. (2005) (109)
- Prevalence, Incidence and Predictors of Severe Anaemia with Zidovudine-Containing Regimens in African Adults with HIV Infection within the Dart Trial (2005) (104)
- Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial (2021) (103)
- T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection. (2005) (98)
- A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. (1995) (90)
- Implementation of an Antiretroviral Access Program for HIV-1-Infected Individuals in Resource-Limited Settings: Clinical Results From 4 African Countries (2007) (82)
- Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021 (2021) (78)
- Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. (2016) (78)
- Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa (2013) (77)
- Mortality in the Year Following Antiretroviral Therapy Initiation in HIV-Infected Adults and Children in Uganda and Zimbabwe (2012) (75)
- Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. (2016) (74)
- Cohort Profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) Monitoring Studies to Evaluate Resistance—HIV drug resistance in sub-Saharan Africa and the Asia-Pacific (2010) (73)
- High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. (2004) (72)
- Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa. (2012) (72)
- Long-Term Antiretroviral Treatment Adherence in HIV-Infected Adolescents and Adults in Uganda: A Qualitative Study (2016) (66)
- Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. (2010) (64)
- Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa. (2015) (61)
- Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial (2017) (60)
- Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial (2017) (60)
- Factors Associated with Intention to Conceive and its Communication to Providers Among HIV Clients in Uganda (2012) (59)
- Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir. (2010) (59)
- Adherence to antiretroviral therapy for HIV in sub-Saharan Africa and Asia: a comparative analysis of two regional cohorts (2017) (58)
- Barriers to Initiation of Pediatric HIV Treatment in Uganda: A Mixed-Method Study (2012) (54)
- Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV. (2021) (53)
- Understanding the influence of depression on self-efficacy, work status and condom use among HIV clients in Uganda. (2011) (50)
- Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. (2018) (47)
- Global threat from drug resistant HIV in sub-Saharan Africa (2012) (46)
- Lymphoid tissue fibrosis is associated with impaired vaccine responses (2018) (46)
- Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa. (2016) (46)
- Impact of HIV Antiretroviral Therapy on Depression and Mental Health Among Clients With HIV in Uganda (2012) (45)
- High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy (2013) (44)
- Therapeutic responses to AZT + 3TC + EFV in advanced antiretroviral naive HIV type 1-infected Ugandan patients. (2002) (44)
- High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy (2013) (44)
- HIV-1 risk and vaccine acceptability in the Ugandan military. (1997) (43)
- Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children. (2013) (42)
- Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial. (2016) (42)
- Quantifying HIV transmission flow between high-prevalence hotspots and surrounding communities: a population-based study in Rakai, Uganda (2020) (41)
- Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure (2016) (40)
- Factors Associated with Condom Use Among HIV Clients in Stable Relationships with Partners at Varying Risk for HIV in Uganda (2010) (38)
- Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial. (2010) (37)
- Glomerular Dysfunction and Associated Risk Factors over 4–5 Years following Antiretroviral Therapy Initiation in Africa (2011) (37)
- Pulmonary function in an international sample of HIV‐positive, treatment‐naïve adults with CD4 counts > 500 cells/μL: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial (2015) (35)
- A Randomized, Controlled, Trial of Short Cycle Intermittent Compared to Continuous Antiretroviral Therapy for the Treatment of HIV Infection in Uganda (2010) (35)
- Multicentre analysis of second-line antiretroviral treatment in HIV-infected children: adolescents at high risk of failure (2017) (35)
- Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda (2009) (35)
- Cost Effectiveness Analysis of Clinically Driven versus Routine Laboratory Monitoring of Antiretroviral Therapy in Uganda and Zimbabwe (2012) (35)
- Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa (2018) (35)
- Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial (2016) (35)
- Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period (2013) (34)
- Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial (2015) (34)
- Oropharyngeal colonization by Streptococcus pneumoniae among HIV-infected adults in Uganda: assessing prevalence and antimicrobial susceptibility. (2006) (34)
- Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children (2017) (34)
- HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in Uganda (2016) (33)
- Characterization of a Subtype D Human Immunodeficiency Virus Type 1 Isolate That Was Obtained from an Untreated Individual and That Is Highly Resistant to Nonnucleoside Reverse Transcriptase Inhibitors (2004) (33)
- Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults (2012) (32)
- Resistance to antiretroviral therapy among patients in Uganda. (2001) (32)
- A qualitative analysis of the economic impact of HIV and antiretroviral therapy on individuals and households in Uganda. (2009) (31)
- Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial (2018) (30)
- Detection of recent HIV infections in African individuals infected by HIV-1 non-B subtypes using HIV antibody avidity. (2008) (30)
- The Lablite project: A cross-sectional mapping survey of decentralized HIV service provision in Malawi, Uganda and Zimbabwe (2014) (30)
- Averted HIV infections due to expanded antiretroviral treatment eligibility offsets risk of transmitted drug resistance: a modeling study (2014) (28)
- Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48‐week randomized comparison with abacavir/zidovudine/lamivudine in HIV‐infected Ugandan adults with low CD4 cell counts (2010) (28)
- Rheumatic Heart Disease Treatment Cascade in Uganda (2017) (28)
- The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children (2016) (27)
- Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults. (2008) (27)
- Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countries. (2012) (27)
- Depression in the Pathway of HIV Antiretroviral Effects on Sexual Risk Behavior Among Patients in Uganda (2012) (26)
- Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study (2014) (26)
- Using nearly full-genome HIV sequence data improves phylogeny reconstruction in a simulated epidemic (2016) (26)
- Plasma Biomarkers of Human Immunodeficiency Virus–Related Systemic Inflammation and Immune Activation in Sub-Saharan Africa Before and During Suppressive Antiretroviral Therapy (2019) (26)
- Response to nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-dose nevirapine. (2009) (26)
- A Pragmatic Approach to HIV-1 Drug Resistance Determination in Resource-Limited Settings by Use of a Novel Genotyping Assay Targeting the Reverse Transcriptase-Encoding Region Only (2013) (26)
- Evolution of Drug Resistance During 48 Weeks of Zidovudine/Lamivudine/Tenofovir in the Absence of Real-Time Viral Load Monitoring (2010) (26)
- HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa (2017) (25)
- Distribution of HLA‐B alleles in a Ugandan HIV‐infected adult population: NORA pharmacogenetic substudy of DART (2011) (25)
- Towards 90-90-90 Target: Factors Influencing Availability, Access, and Utilization of HIV Services—A Qualitative Study in 19 Ugandan Districts (2018) (25)
- Human Immunodeficiency Virus-Specific Responses in Adult Ugandans: Patterns of Cross-Clade Recognition (2005) (25)
- Impact of the N348I Mutation in HIV-1 Reverse Transcriptase on Nonnucleoside Reverse Transcriptase Inhibitor Resistance in Non-Subtype B HIV-1 (2011) (24)
- Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial (2018) (24)
- Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial. (2019) (24)
- Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial (2018) (24)
- Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial (2018) (23)
- Efficacy of convalescent plasma for treatment of COVID-19 in Uganda (2021) (23)
- A Single CD4 Test with 250 Cells/Mm3 Threshold Predicts Viral Suppression in HIV-Infected Adults Failing First-Line Therapy by Clinical Criteria (2013) (22)
- Resistance to Antiretroviral Therapy Among Patients in Uganda (2001) (22)
- The impact of first year adherence to antiretroviral therapy on long‐term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe (2012) (22)
- Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial (2018) (21)
- Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. (2021) (21)
- Translocated microbiome composition determines immunological outcome in treated HIV infection (2021) (20)
- HIV Type 1 Disease Progression to AIDS and Death in a Rural Ugandan Cohort Is Primarily Dependent on Viral Load Despite Variable Subtype and T-Cell Immune Activation Levels. (2015) (20)
- Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy. (2013) (20)
- Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda. (2018) (20)
- Building capacity for the assessment of HIV drug resistance: experiences from the PharmAccess African Studies to Evaluate Resistance network. (2012) (19)
- Implementation of antiretroviral therapy for life in pregnant/breastfeeding HIV+ women (Option B+) alongside rollout and changing guidelines for ART initiation in rural Zimbabwe: the Lablite Project experience (2017) (18)
- Altered intestinal permeability and fungal translocation in Ugandan children with HIV. (2020) (18)
- HIV and pericardial fat are associated with abnormal cardiac structure and function among Ugandans (2019) (18)
- ORPHANHOOD PREDICTS DELAYED ACCESS TO CARE IN UGANDAN CHILDREN (2009) (17)
- Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children (2016) (17)
- A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial (2022) (17)
- Response to antiretroviral therapy of HIV type 1-infected children in urban and rural settings of Uganda. (2012) (16)
- Identification of gaps for implementation science in the HIV prevention, care and treatment cascade; a qualitative study in 19 districts in Uganda (2016) (16)
- HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe. (2014) (16)
- Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women (2018) (15)
- Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study (2014) (15)
- A Human-Centered Approach to CV Care (2018) (15)
- Latent Tuberculosis Infection and Subclinical Coronary Atherosclerosis in Peru and Uganda. (2021) (15)
- Brief Report: Prevalence of Latent Rheumatic Heart Disease Among HIV-Infected Children in Kampala, Uganda (2016) (15)
- Enhanced infection prophylaxis reduces mortality in severely immunosuppressed HIV-infected adults and older children initiating antiretroviral therapy in Kenya, Malawi, Uganda and Zimbabwe: the REALITY trial (2016) (14)
- Development and Evaluation of an Affordable Real-Time Qualitative Assay for Determining HIV-1 Virological Failure in Plasma and Dried Blood Spots (2013) (14)
- Population level usage of health services, and HIV testing and care, prior to decentralization of antiretroviral therapy in Agago District in rural Northern Uganda (2015) (14)
- Poor immunological recovery among severely immunosuppressed antiretroviral therapy-naïve Ugandans (2013) (14)
- Impact of routine laboratory monitoring over 5 years after antiretroviral therapy (ART)initiation on clinical disease progression of HIV-infected African adults: the DART Trial finalresults (2009) (13)
- Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy–Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial (2019) (13)
- Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa (2017) (13)
- Hepatitis B serological markers and plasma DNA concentrations (2017) (13)
- Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa (2015) (13)
- Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children (2016) (12)
- ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing (2021) (12)
- Second-line HIV Treatment in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance (2016) (12)
- Anthropometric Measurements and Lipid Profiles to Detect Early Lipodystrophy in Antiretroviral Therapy Experienced HIV-Infected Children in the Chapas-3 Trial (2014) (12)
- ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing (2021) (12)
- Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIV (2018) (11)
- Shifting human resources for health in the context of ART provision: qualitative and quantitative findings from the Lablite baseline study (2016) (11)
- A Case of Cryptococcal Lymphadenitis in an HIV-Infected Child. (2011) (11)
- Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIV (2018) (11)
- Emergence and evolution of drug resistance in the absence of viral load monitoring during 48 weeks of Combivir/Tenofovir within the DART Trial. (2007) (11)
- Shifting human resources for health in the context of ART provision: qualitative and quantitative findings from the Lablite baseline study (2016) (11)
- Impact of decentralisation of antiretroviral therapy services on HIV testing and care at a population level in Agago District in rural Northern Uganda: results from the Lablite population surveys. (2017) (11)
- Stevens - Johnson syndrome due to nevirapine. (2005) (11)
- Previous antiretroviral drug use compromises standard first-line HIV therapy and is mediated through drug-resistance (2018) (11)
- Coronary artery calcium, HIV and inflammation in Uganda compared with the USA (2019) (10)
- Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries (2017) (10)
- Virological findings from the SARA trial: boosted PI monotherapy as maintenance second-line ART in Africa (2010) (10)
- Therapeutic drug monitoring of nevirapine in saliva in Uganda using high performance liquid chromatography and a low cost thin-layer chromatography technique (2014) (10)
- Clinical course of human immunodeficiency virus type 1 associated pulmonary tuberculosis during short-course antituberculosis therapy. (1997) (9)
- Pregnancy and pregnancy outcome among women in the DART trial. (2007) (9)
- The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa. (2020) (9)
- High Level of Viral Suppression and Low Switch Rate to Second-Line Antiretroviral Therapy among HIV-Infected Adult Patients Followed over Five Years: Retrospective Analysis of the DART Trial (2014) (9)
- Sexual behaviour among persons living with HIV/AIDS in Kampala, Uganda. (2010) (9)
- Prevalence of viral load suppression, predictors of virological failure and patterns of HIV drug resistance after 12 and 48 months on first-line antiretroviral therapy: a national cross-sectional survey in Uganda (2020) (9)
- Impact of Integrase Inhibition Compared With Nonnucleoside Inhibition on HIV Reservoirs in Lymphoid Tissues (2019) (9)
- Clinical Differences between Younger and Older Adults with HIV/AIDS Starting Antiretroviral Therapy in Uganda and Zimbabwe: A Secondary Analysis of the DART Trial (2013) (9)
- ,for the DART Trial Team. A randomised trial of monitoring practice and structured treatment interruptions in the management of antiretroviral therapy in adults with HIV infection in Africa: the DART trial (2003) (9)
- Pharmacokinetics of Lopinavir-Ritonavir with and without Nonnucleoside Reverse Transcriptase Inhibitors in Ugandan HIV-Infected Adults (2010) (9)
- High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations. (2021) (9)
- Clinical Evaluation of an Affordable Qualitative Viral Failure Assay for HIV Using Dried Blood Spots in Uganda (2016) (8)
- Subclinical Vascular Disease in Children with HIV in Uganda is Associated with Intestinal Barrier Dysfunction. (2019) (8)
- Therapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: a Phase I safety study. (2011) (8)
- Glomerular dysfunction and associated risk factors through four years following initiation of ART in adults with HIV Infection in Africa in the DART trial (2008) (8)
- Prospective cohort study of the impact of antiretroviral therapy on employment outcomes among HIV clients in Uganda. (2013) (8)
- Pregnancy rates and outcomes among women on triple-drug antiretroviral therapy (ART) in the DART trial. (2009) (8)
- Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial (2018) (7)
- Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial (2018) (7)
- Impact of Integrase Inhibition compared to non-nucleoside inhibition on HIV reservoirs in Lymphoid Tissues. (2019) (7)
- Increased monocyte and T-cell activation in treated HIV+ ugandan children: associations with gut alteration and HIV factors. (2020) (7)
- Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda. (2020) (7)
- First-line HIV treatment failures in non-B subtypes and recombinants: a cross-sectional analysis of multiple populations in Uganda (2019) (7)
- Single nucleotide polymorphisms in HLA alleles are associated with HIV-1 viral load in demographically diverse, ART-naïve participants from the START trial. (2019) (7)
- O087 Leveraging existing HIV/AIDS infrastructure for rheumatic heart disease care in Uganda: a collaborative disease surveillance and management program (2014) (7)
- Sex, HIV Status, and Measures of Cardiac Stress and Fibrosis in Uganda (2021) (7)
- Patient-level benefits associated with decentralization of antiretroviral therapy services to primary health facilities in Malawi and Uganda. (2018) (6)
- Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. (2022) (6)
- failure: prospective cohort in sub-Saharan Africa (2012) (6)
- Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda (2020) (6)
- Characterization of penicillin intermediate serotypes of Streptococcus pneumoniae carried by human immunodeficiency virus-infected adults and healthy children in Uganda. (2007) (5)
- Improved Adherence to Antiretroviral Therapy Observed Among HIV-Infected Children Whose Caregivers had Positive Beliefs in Medicine in Sub-Saharan Africa (2016) (5)
- Sex modifies the association between HIV and coronary artery disease among older adults in Uganda (2022) (5)
- Using Exclusion-Based Sample Preparation (ESP) to Reduce Viral Load Assay Cost (2015) (5)
- Eff ect of pretreatment HIV-1 drug resistance on immunological , virological , and drug-resistance outcomes of fi rst-line antiretroviral treatment in sub-Saharan Africa : a multicentre cohort study (2011) (5)
- Inspiring women: Experimental evidence on sharing entrepreneurial skills in Uganda (2017) (5)
- HIV-1 drug resistance in antiretroviral-naive patients in sub-Saharan Africa. (2012) (5)
- Lipidome Association with Vascular Disease and Inflammation in HIV+ Ugandan Children. (2021) (5)
- Long-term virological outcomes, failure and acquired resistance in a large cohort of Ugandan children. (2019) (5)
- Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial (2022) (4)
- Altered Intestinal Permeability and Fungal Translocation in Ugandan Children With Human Immunodeficiency Virus (2020) (4)
- Failure is not an option: Barriers to HIV treatment adherence in Kampala, Uganda. (2020) (4)
- Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa (2016) (4)
- Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial (2022) (4)
- Micronutrients, Metabolic Complications and Inflammation in Ugandan Children with HIV. (2020) (4)
- Need for review of prevention of mother-to-child transmission practice especially in discordant couples: a case of mother-to-child transmission of HIV during breast feeding by a mother who tested HIV negative antenatally. (2007) (4)
- Monocyte activation in persons living with HIV and tuberculosis coinfection. (2020) (4)
- Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets (2017) (4)
- Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI) (2021) (4)
- A Mixed Methods, Observational Investigation of Physical Activity, Exercise, and Diet Among Older Ugandans Living With and Without Chronic HIV Infection (2020) (4)
- A qualitative exploration of the impact of HIV and ART on social disruption and household continuity in Uganda (2011) (4)
- A randomised trial of monitoring practice and structured treatment interruptions in the management of antriretroviral therapy in adults with HIV infection in Africa. (2003) (4)
- Pretreatment HIV-1 drug resistance in Africa. (2013) (3)
- Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda (2014) (3)
- Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda (2014) (3)
- Plasma inflammatory biomarkers predict CD4+ T-cell recovery and viral rebound in HIV-1 infected Africans on suppressive antiretroviral therapy. (2020) (3)
- Superior virological suppression with nevirapine/zidovudine/lamivudine versus abacavir/zidovudine/lamivudine without evidence of clinical benefit to 48 weeks: a randomised comparison in patients with low CD4 counts in Africa. (2007) (3)
- Immunological response to boosted PI-containing second line ART after switching for clinical/immunological criteria is comparable to response to first-line in patients with low CD4 counts in Africa. (2008) (3)
- O086 Does HIV infection modify the risk of RHD? Initial echocardiographic screening experience at the Joint Clinical Research Centre in Kampala, Uganda (2014) (3)
- A Randomized, Controlled, Non-inferiority Trial of Two Short Cycle Intermittent Regimens Compared to Continuous Antiretroviral Therapy for the Treatment of Chronic HIV Infection in Uganda (2008) (3)
- Reduced and highly diverse peripheral HIV-1 reservoir in virally suppressed patients infected with non-B HIV-1 strains in Uganda (2022) (3)
- Subclinical Vascular Disease in Children With Human Immunodeficiency Virus in Uganda Is Associated With Intestinal Barrier Dysfunction (2021) (3)
- P075 Efficacy and safety of switching to EVG/COBI/FTC/TAF in virologically suppressed women (2017) (2)
- Long-term HIV treatment outcomes and associated factors in sub-Saharan Africa: multicountry longitudinal cohort analysis (2022) (2)
- Isoniazid Adherence Reduces Mortality and Incident Tuberculosis at 96 Weeks Among Adults Initiating Antiretroviral Therapy With Advanced Human Immunodeficiency Virus in Multiple High-Burden Settings (2022) (2)
- Scaling up antiretroviral therapy : experience of the Joint Clinical Research Centre (JCRC) access programme (2006) (2)
- HIV-1 Viral Load and Resistance in Genital Secretions in Patients Taking Protease-Inhibitor-Based Second-Line Therapy in Africa (2017) (2)
- Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial (2022) (2)
- Residual Activity of Two HIV Antiretroviral Regimens Prescribed without Virological Monitoring (2011) (2)
- Discordance between virological/immunological and clinical outcomes at 48 weeks, in a randomised comparison of ZDV/3TC/NVP and ZDV/3TC/ABC in patients with low CD4 counts in Africa. (2007) (2)
- Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial (2022) (2)
- Second-line treatment in sub-Saharan Africa: week 144 follow-up of the EARNEST trial (2015) (2)
- Persistence of traditional and emergence of new structural drivers and factors for the HIV epidemic in rural Uganda; A qualitative study (2019) (2)
- Measuring and Valuing Informal Care for Economic Evaluation of HIV/AIDS Interventions: Methods and Application in Malawi. (2016) (2)
- 12-week raltegravir-intensified quadruple therapy versus triple first-line ART reduces viral load more rapidly but does not reduce mortality in severely immunosuppressed African HIV-infected adults and older children: the REALITY trial (2016) (2)
- Relationship between economic insecurity, inflammation, monocyte activation and intestinal integrity in children living with HIV in Uganda (2020) (2)
- Lessons for test and treat in an antiretroviral programme after decentralisation in Uganda: a retrospective analysis of outcomes in public healthcare facilities within the Lablite project. (2019) (2)
- Differences in body circumferences, skin‐fold thicknesses and lipid profiles among HIV‐infected African children on and not on stavudine (2012) (1)
- The Association of Kidney Disease with Abnormal Cardiac Structure and Function among Ugandans with HIV Infection. (2020) (1)
- Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial. (2023) (1)
- Clinical Outcomes, Echocardiographic Findings, and Care Quality Metrics for People Living with HIV and Rheumatic Heart Disease in Uganda. (2021) (1)
- Is HLA-B*5701 associated with clinically diagnosed hypersensitivity to abacavir in Ugandan HIV-infected adults? (2011) (1)
- Determinants of Clinician Knowledge on Aging and HIV/AIDS: A Survey of Practitioners and Policy Makers in Kampala District, Uganda (2013) (1)
- Immune restoration over 5 years on ART among patients initiating treatment with advanced immune deficiency in the DART trial in Uganda and Zimbabwe. (2010) (1)
- New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings. (2021) (1)
- Sex modulates the association between inflammation and coronary atherosclerosis among older Ugandan adults with and without HIV (2022) (1)
- Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30–49 vs ≥50 mL/min (2019) (1)
- HPTN 069/ACTG A5305: phase II study of maraviroc-containing regimens for HIV PrEP in US women; Postive impact of a randomized controlled trial of the Uthando Lwethu ("Our Love") intervention on rates of couples HIV testing in rural South Africa (2016) (1)
- Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials (2021) (1)
- Correction: Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial (2016) (1)
- Abstract 18798: Application of the HIV/AIDS Treatment Cascade Model to Rheumatic Heart Disease in Uganda (2014) (1)
- Bortezomib As Frontline Therapy in the Management of TTP (2021) (1)
- Differences in Resistance Mutations in Non-B Subtypes at First-line Failure in Africa (2015) (1)
- Correction: Long-Term Antiretroviral Treatment Adherence in HIV-Infected Adolescents and Adults in Uganda: A Qualitative Study (2017) (1)
- Sex-specific performance of the ASCVD pooled cohort equation risk calculator as a correlate of coronary artery calcium in Kampala, Uganda (2022) (1)
- Long-term randomised comparison of clinical outcomes following ART initiation with triple-nucleoside (Combivir/Abacavir) or NNRTI-based (Combivir/Nevirapine) therapy in Africa: the NORA substudy of the DART trial. (2009) (1)
- Rotavirus Infection in HIV-1 Infected Individuals at an urban HIV/AIDS Treatment Center in Kampala, Uganda (2014) (1)
- A Sex-Stratified Analysis of Monocyte Phenotypes Associated with HIV Infection in Uganda (2021) (1)
- Potent HBV therapy and availability of laboratory monitoring fail to abrogate increased risk of death in HBV-HIV-co-infected individuals in the DART study (2011) (0)
- 80. Heme Oxygenase-1 Gene promoter and associations with inflammation and subclinical vascular disease in Ugandan adolescents with and without HIV (2021) (0)
- Persistent galactorrhea in a postmenopausal woman with herpes zoster and HIV-1 infection (2006) (0)
- Antiretroviral Drug Resistance Mutations in HIV-1 Infected Ugandan Children Perinatally Exposed to Single Dose Nevirapine Following Virologic Failure to an NNRTI Based Regimen (2010) (0)
- Persistent immune activation and altered gut integrity over time in a longitudinal study of Ugandan youth with perinatally acquired HIV (2023) (0)
- mining HIV-1 virological failure in plasma and dried blood spots (2013) (0)
- Performance of V3-based HIV-1 sero subtyping in HIV endemic areas. (2011) (0)
- Different evolution of resistance uncovered by single genome sequencing (SGS) analysis of patients with long term virological failure during continuous or interrupted therapy. (2010) (0)
- Enhanced prophylaxis with antiretroviral therapy for advanced HIV in Africa (2017) (0)
- Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
- OC 8450 ABSENCE OF MINORITY HIV-1 DRUG-RESISTANT VARIANTS FOLLOWING MOTHER-TO-CHILD TRANSMISSION DOES NOT PREDICT VIROLOGIC SUCCESS OF FIRST-LINE ANTIRETROVIRAL THERAPY (2019) (0)
- 1284. Study of Single Nucleotide Polymorphisms Associated with HIV-1 Set-Point Viral Load in Antiretroviral Therapy-Naïve HIV-Positive Participants of the START Study (2018) (0)
- Early mortality following ART initiation in HIV-infected adults and children in Uganda and Zimbabwe (2010) (0)
- Iconographies supplémentaires de l'article : Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial (2016) (0)
- Reduced and highly diverse peripheral HIV-1 reservoir in virally suppressed patients infected with non-B HIV-1 strains in Uganda (2022) (0)
- Effect of PI resistance mutations on viral load in patients on PI monotherapy (2016) (0)
- Lack of minority K65R resistant viral populations detected after repeated interruptions of tenofovir DF/ zidovudine/lamivudine. (2009) (0)
- Shifting Human Resources for Health in the context of ART provision in primary care facilities: qualitative and quantitative findings from the Lablite Baseline Survey (2013) (0)
- Impact of a lopinavir/ritonavir (Kaletra) based second-line antiretroviral therapy regimen on lipid and lipoprotein profiles in an African setting. (2008) (0)
- Estimation of virological residual activity on a regimen of abacavir/zidovudine/lamivudine (ABC/3TC/ZDV). (2010) (0)
- Abstract 14442: Tuberculosis-Specific Cell-Mediated Immune Responses Are Associated With Coronary Artery Atherosclerosis Among Persons With and Without HIV in Uganda (2020) (0)
- Phenotypic data to guide selection of reverse transcriptase inhibitors in second-line therapy following extended virological failure in Uganda (2009) (0)
- Impact of daily cotrimoxazole prophylaxis in severely immunosuppressed adults in Africa started on combination ART in the DART trial. (2009) (0)
- Development and evaluation of an affordable real-time qualitative assay for deter-1 mining HIV-1 virological failure in plasma and dried blood spots 2 3 (2013) (0)
- Inferring HIV-1 transmission networks and sources of epidemic spread in Africa with deep-sequence phylogenetic analysis (2019) (0)
- Therapeutic drug monitoring of nevirapine in saliva in Uganda using high performance (2014) (0)
- Identification of gaps for implementation science in the HIV prevention, care and treatment cascade; a qualitative study in 19 districts in Uganda (2016) (0)
- Iconographies supplémentaires de l'article : Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study (2012) (0)
- Pulmonary Effects of Immediate Versus Deferred Antriretroviral Treatment Initiation: Final Follow-Up Results from the Randomized Strategic Timing of Antiretroviral Treatment (START) Pulmonary Substudy (2018) (0)
- ActivationInfection Is Associated with Immune Depletion of Regulatory T Cells in HIV (2005) (0)
- Impact of the Relationship between Anaemia and Systemic Inflammation on the Risk of Incident Tuberculosis and Death in Persons with Advanced HIV: A Sub-Analysis of the REMEMBER Trial (2022) (0)
- Abstract 11289: Sedentary Time in Uganda: Influence of Sex and HIV Status and Associations with Atherosclerotic Cardiovascular Disease Risk (2021) (0)
- Lessons from an international trial evaluating vaccination strategies for recovered inpatients with COVID-19 (VATICO) (2022) (0)
- Shifting ART Service provision: Health care workers' experience and challenges in Malawi and Zimbabwe. (2012) (0)
- Detection of novel HIV-1 drug resistance mutations by support vector analysis of deep sequence data and experimental validation (2019) (0)
- Supporting Information S1 (2010) (0)
- Longitudinal changes in subclinical vascular disease in Ugandan youth with HIV. (2022) (0)
- Different evolution of resistance uncovered by single-genome sequencing analysis of patients with long-term virological failure during continuous or interrupted antiretroviral therapy (2010) (0)
- Previous antiretroviral drug use compromises standard first-line HIV therapy and is mediated through drug-resistance (2018) (0)
- Risk of WHO 4 events and death by current CD4 on ART in the DART trial: the impact of CD4-dependent reporting bias. (2010) (0)
- Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status. (2020) (0)
- Body and mind: Experimental evidence from women living with HIV (2021) (0)
- Most HIV-infected individuals on antiretroviral therapy ( ART ) in low and middle-income countries are treated following the World Health (2014) (0)
- The impact of the N348I mutation in HIV-1 reverse transcriptase, on non- (2011) (0)
- Effect of WHO stage 3/4 events after ART initiation on survival of HIV-infected African adults in the DART trial. (2009) (0)
- Impact of sub-optimal HIV viral control on activated T-cells: an earnest sub study. (2023) (0)
- Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of HIV in Low- and Middle-Income Countries (LMICs). (2022) (0)
- Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV (2023) (0)
- O125 Impact of efavirenz and nevirapine on pharmacokinetics of lopinavir/ritonavir as tablets and capsules in African patients (2008) (0)
- Lablite: Training needs for roll out of ART in Uganda and Zimbabwe using optimisation of clinical skills and minimisation of routine laboratory monitoring (2013) (0)
- Low risk of alanine aminotransferase (ALT) flares in HBV/HIV coinfected patients starting HAART in the DART Study (2011) (0)
- ‘…So that’s why we hide, we don’t want them to know’— challenges to antiretroviral therapy adherence in Kampala, Uganda (2022) (0)
- Correction: Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI) (2021) (0)
- Prevalence of minority Human Immunodeficiency virus multi-drug resistant mutations among patients failing a Nucleoside Reverse Transcriptase Inhibitor based regimen in Uganda (2021) (0)
This paper list is powered by the following services:
Other Resources About Cissy Kityo
What Schools Are Affiliated With Cissy Kityo?
Cissy Kityo is affiliated with the following schools:
